FINWIRES · TerminalLIVE
FINWIRES

Frontier Lithium完成1500万加元包销发行

By

-- Frontier Lithium (FL.V) 周四宣布,已完成此前公布的包销发行,由 BMO Capital Markets 牵头的承销团承销了公司股份。 该公司表示,此次发行共售出 2000 万份股份,每份售价 0.75 加元,公司募集资金总额为 1500 万加元。 每份股份包含一股普通股和半份普通股认股权证。每份完整的认股权证可在发行完成之日起两年内以每股 1.00 加元的价格认购一股普通股。 该公司补充道,共有六位内部人士参与了此次发行,共认购了 136,668 份股份,募集资金总额为 102,501 加元。 公司表示,所得净收益将用于推进PAK锂矿项目,并补充说,这些资金将用于完成更新后的矿山和选矿厂技术报告,促进与政府资助或成本分摊的基础设施项目相关的活动、许可审批、推进锂转化研究,以及支付一般行政和公司开支。 公司总裁兼首席执行官特雷弗·沃克表示:“此次融资标志着PAK锂矿项目推进的重要一步,它将支持关键的工程、许可审批和下游项目,从而持续降低资产风险,并支持公司未来项目融资的努力。我们很高兴看到长期股东、新机构投资者和内部人士的持续支持,这增强了我们对Frontier公司已为下一阶段市场做好充分准备的信心——支持北美锂供应安全,推进分阶段降低风险的战略,并将该项目定位为新兴国内关键矿产供应链中的战略资产。” 该公司股票在多伦多证券交易所创业板的最新交易价格为0.62美元,与前一日持平。

Related Articles

Research

Research Alert: CFRA Keeps Buy Opinion On Shares Of Firstenergy Corp.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We trim our 12-month target by $1 to $55, 20.0x our next-12-month EPS view of $2.75, a premium to its five-year average of 15.6x. We reduce our 2026 EPS view by $0.02 to $2.72 and 2027 EPS by $0.01 to $2.93. The Q1 core EPS increase (+7.5% Y/Y) breaks a three-quarter streak of declines, and we see continued momentum throughout our forecast horizon. We see positive data center demand trends, with long-term contracted demand (4.3 GW) up 4% since February 2026 (4.1 GW) and up 47% since February 2025 (2.9 GW), while pipeline demand (14.9 GW) is up 15% since February 2026 (12.9 GW) and has more than doubled since February 2025 (6.1 GW). FE has reduced base O&M by over $200M (15%) since 2022, with Q1 2026 showing an additional ~5% YoY decline, while simultaneously improving reliability metrics. We think FE's cost discipline, service quality improvement, and competitive rate positioning should translate into more favorable rate case outcomes, reduced disallowance risk, and potentially higher allowed ROEs.

$FE
Sectors

Sector Update: Consumer

Consumer stocks were higher Thursday afternoon, with the State Street Consumer Staples Select Sector SPDR ETF (XLP) rising 1.4% and the State Street Consumer Discretionary Select Sector SPDR ETF (XLY) increasing 0.4%.In corporate news, Lamb Weston (LW) shares rose 1.6% after shareholder Starboard Value said in a letter to the board Thursday that the company should hold an investor day and reset earnings to a normalized level.

$LW
Australia

Market Chatter: FDA Panel Votes Against Benefits of AstraZeneca's Breast Cancer Drug

The US Food and Drug Administration's Oncology Drugs Advisory Committee rejected the benefits AstraZeneca's (AZN) Camizestrant drug candidate to treat breast cancer, Bloomberg reported Thursday.Six committee members voted against the drug due to disagreement over the trial design and the potential implications in the clinical setting, according to Bloomberg.The drug trial met is primary endpoint of progression-free survival as well as the progression-free survival 2 endpoint, however, FDA does not consider PFS2 a suitable endpoint for regulatory decision making, according to a briefing document.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $189.60, Change: $+4.40, Percent Change: +2.37%

$AZN